JP6916185B2 - Btk阻害剤としてのイソキノロン類 - Google Patents

Btk阻害剤としてのイソキノロン類 Download PDF

Info

Publication number
JP6916185B2
JP6916185B2 JP2018536252A JP2018536252A JP6916185B2 JP 6916185 B2 JP6916185 B2 JP 6916185B2 JP 2018536252 A JP2018536252 A JP 2018536252A JP 2018536252 A JP2018536252 A JP 2018536252A JP 6916185 B2 JP6916185 B2 JP 6916185B2
Authority
JP
Japan
Prior art keywords
mmol
formula
pharmaceutically acceptable
compounds
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018536252A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501927A5 (enExample
JP2019501927A (ja
Inventor
ボサナック,トッド
ベントツィーン,イェルク
バーク,マイケル・ジェイソン
ディサルボ,ダレン・トッド
マオ,ワン
ソリマンザデー,ファリバ
ウェストブルック,ジョン
ション,ツァオミン
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング, ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2019501927A publication Critical patent/JP2019501927A/ja
Publication of JP2019501927A5 publication Critical patent/JP2019501927A5/ja
Application granted granted Critical
Publication of JP6916185B2 publication Critical patent/JP6916185B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2018536252A 2016-01-13 2017-01-12 Btk阻害剤としてのイソキノロン類 Active JP6916185B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662278085P 2016-01-13 2016-01-13
US62/278,085 2016-01-13
PCT/US2017/013100 WO2017123695A1 (en) 2016-01-13 2017-01-12 Isoquinolones as btk inhibitors

Publications (3)

Publication Number Publication Date
JP2019501927A JP2019501927A (ja) 2019-01-24
JP2019501927A5 JP2019501927A5 (enExample) 2020-02-13
JP6916185B2 true JP6916185B2 (ja) 2021-08-11

Family

ID=57907002

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018536252A Active JP6916185B2 (ja) 2016-01-13 2017-01-12 Btk阻害剤としてのイソキノロン類

Country Status (4)

Country Link
US (1) US10570118B2 (enExample)
EP (1) EP3402789B1 (enExample)
JP (1) JP6916185B2 (enExample)
WO (1) WO2017123695A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017163078A1 (en) * 2016-03-24 2017-09-28 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as dbu inhibitors
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US20220227729A1 (en) * 2019-05-21 2022-07-21 Bayer Aktiengesellschaft Identification and use of kras inhibitors
BR112021023110A2 (pt) * 2019-05-23 2022-04-12 Novartis Ag Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN115650851A (zh) * 2022-11-10 2023-01-31 无锡双启科技有限公司 一种2-氟-4-溴-6-甲基苯甲酸甲酯的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9608435D0 (en) 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
WO2003015776A1 (en) 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
EP1436265A4 (en) 2001-09-27 2004-12-15 Smithkline Beecham Corp CHEMICALS
FR2881426B1 (fr) 2005-02-03 2007-03-30 Aventis Pharma Sa Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation
US7589214B2 (en) 2006-04-11 2009-09-15 Vertex Pharmaceuticals Incorporated Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
PL2526933T3 (pl) 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
SG10201508035TA (en) 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
DK2242749T3 (da) * 2008-02-05 2013-06-17 Hoffmann La Roche Nye pyridinoner og pyridazinoner
EP2297142B1 (en) * 2008-06-24 2015-10-14 F. Hoffmann-La Roche AG Novel substituted pyridin-2-ones and pyridazin-3-ones
WO2010012690A1 (en) 2008-07-29 2010-02-04 Université de Liège A genetic marker test for brachyspina and fertility in cattle
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
AU2010341229A1 (en) 2009-12-17 2012-08-02 Merck Patent Gmbh Sphingosine kinase inhibitors
MX2012013622A (es) 2010-05-31 2013-02-01 Ono Pharmaceutical Co Derivado de purinona.
EP2603216A4 (en) 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
JP5859640B2 (ja) * 2011-05-17 2016-02-10 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ブルトンチロシンキナーゼ阻害剤
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CN104080789B (zh) 2012-01-31 2016-05-11 南京奥昭生物科技有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
WO2013157022A1 (en) * 2012-04-20 2013-10-24 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
MA37830B1 (fr) 2012-08-10 2018-09-28 Boehringer Ingelheim Int Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk)
CA2881761A1 (en) 2012-09-13 2014-03-20 Christine E. Brotherton-Pleiss Inhibitors of bruton's tyrosine kinase
CN105008344B (zh) 2012-11-02 2017-07-25 辉瑞公司 布鲁顿氏酪氨酸激酶抑制剂
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
EP3042899A1 (en) * 2013-09-03 2016-07-13 Carna Biosciences Inc. Novel 2,6-diaminopyrimidine derivative
JP2016535764A (ja) * 2013-10-04 2016-11-17 ビヨンド オンコロジー ファーマシューティカル エルエルシー ブルトンのチロシンキナーゼの阻害剤
US9828364B2 (en) 2014-01-29 2017-11-28 Boehringer Ingelheim International Gmbh Pyrazole compounds as BTK inhibitors
PE20181074A1 (es) 2015-12-16 2018-07-04 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de btk

Also Published As

Publication number Publication date
EP3402789B1 (en) 2020-03-18
EP3402789A1 (en) 2018-11-21
US20190023686A1 (en) 2019-01-24
JP2019501927A (ja) 2019-01-24
US10570118B2 (en) 2020-02-25
WO2017123695A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
JP6976947B2 (ja) 自己免疫疾患の処置に有用なビピラゾリル誘導体
JP6348492B2 (ja) ブルトン型チロシンキナーゼ(btk)阻害剤としてのヘテロ芳香族化合物
JP6486954B2 (ja) Btk阻害剤としてのピラゾール化合物
JP6495886B2 (ja) Btk阻害剤としての複素環式芳香族化合物
JP2019501927A (ja) Btk阻害剤としてのイソキノロン類
CA2971024C (en) Fused ring heteroaryl compounds and their use as trk inhibitors
RU2674701C2 (ru) Аминопиридазиноновые соединения в качестве ингибиторов протеинкиназы
KR102607934B1 (ko) 바닌 억제제로서의 헤테로방향족 화합물
CN104837825A (zh) 鲁顿酪氨酸激酶抑制剂
RU2662810C2 (ru) Хиназолины в качестве ингибиторов киназы
EP3740206A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP6403751B2 (ja) 5−チアゾールカルボキサミン誘導体及びbtk阻害剤としてのその使用
JP2011510967A (ja) 新規複素環化合物
CN120530120A (zh) 可用作mk2激酶的降解剂的化合物和组合物
BR102016029685A2 (pt) compostos heteroaromáticos como inibidores de btk
HK1256795B (en) Bipyrazolyl derivatives useful for the treatment of autoimmune diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210629

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210715

R150 Certificate of patent or registration of utility model

Ref document number: 6916185

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250